<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4446">
  <stage>Registered</stage>
  <submitdate>3/03/2006</submitdate>
  <approvaldate>3/03/2006</approvaldate>
  <nctid>NCT00299676</nctid>
  <trial_identification>
    <studytitle>An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period</studytitle>
    <scientifictitle>An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CR004816</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer Disease</healthcondition>
    <healthcondition>Dementia</healthcondition>
    <healthcondition>Galantamine</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Galantamine (Reminyl)

001 - Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet


Treatment: drugs: Galantamine (Reminyl)
Use of Reminyl according to approved NZ data sheet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Investigate the change in cognitive functioning, clinical and functional improvement, in patients treated with REMINYL in a naturalistic setting.</outcome>
      <timepoint>Baseline, month 3, month 6, month 12 and month 18.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Development of information regarding treatment expectations that can be used for communicating with patients and supporters.</outcome>
      <timepoint>Baseline, month 3, month 6, month 12 and month 18.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gain usage experience in a clinical practice setting that can be used for communicating treatment expectations to patients and carers.</outcome>
      <timepoint>Baseline, month 3, month 6, month 12 and month 18.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients prescribed with galantamine according to the approved New Zealand Data Sheet

          -  The clinical decision to prescribe Galantamine must have been made before and
             independently of the decision to enroll the patient in this observational study

          -  The patient should not have commenced Galantamine treatment before the baseline visit

          -  Patients must be currently living at home (i.e. not in permanent residential care)

          -  Availability of a supporter who has regular contact with the patient</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients having known hypersensitivity to Galantamine

          -  Having severe liver impairment or severe kidney impairment

          -  Suffering from an uncontrolled medical condition other than dementia

          -  Being treated, or previously treated, with another cholinesterase inhibitor or other
             cholinomimetics (medications for treating Alzheimer's disease)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>61</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Auckland</hospital>
    <hospital> - Christchurch Nz</hospital>
    <hospital> - Hamilton</hospital>
    <hospital> - Porirua</hospital>
    <hospital> - Tauranga</hospital>
    <postcode> - Auckland</postcode>
    <postcode> - Christchurch Nz</postcode>
    <postcode> - Hamilton</postcode>
    <postcode> - Porirua</postcode>
    <postcode> - Tauranga</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this observational study is to investigate the changes in cognitive
      functioning, behavior, and functional improvement in Alzheimer's disease patients treated
      with Galantamine who are living at home (i.e. not in permanent residential care), and to
      obtain information regarding usual clinical practice that can be used for communicating
      treatment expectations to patients and supporters.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00299676</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen-Cilag Pty Ltd Clinical Trial</name>
      <address>Janssen-Cilag Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>